Lutz Bonacker from CSL Behring tells us about the unique aspects of working with plasma-derived medicines and how they have shaped the company’s approach to working with and for patients.
NICE has rejected CSL Behring’s alpha1-proteinase inhibitor Respreeza for treating genetic emphysema in draft guidance, saying that it would cost a massive £8 million to give a patient a ye